遺伝子治療

• 金田 安史

  Division of Gene Therapy Science, Graduate School of Medicine

書誌事項

タイトル別名

• Gene Therapy

抄録

Ten years have already passed since the first gene therapy clinical trial was started in USA. As of February 2001, more than 400 protocols have been proposed and approximately 3400 patients joined gene therapy clinical trials. Although no remarkable success has not yet recognized, positive signs are emerging in several diseases such as SCID-X1, hemophilia B, arteriosclerosis obliterance and ischemic heart disease. All of the gene therapy trials are supplement therapy that enhances cellular functions defective in patients by the expression of normal genes without correction of mutated genes. Based on this concept, determination of target genes to induce and promote a disease appears to be the most important issue for the success of gene therapy. Unfortunately, no success has been obtained in cancer gene therapy. Although there are many reasons for the difficulty of cancer gene therapy, one of the main reasons is that cancer molecular biology is still insufficient for analyzing carcinogenesis and cancer progression. Much attensions are being paid on the improvement of gene delivery systems. This is absolutely important, but scientists involved in gene therapy should recognize much more the importance of molecular biology of various intractable diseases.

収録刊行物

• 皮膚の科学

  皮膚の科学 1 (1), 7-14, 2002

  日本皮膚科学会大阪地方会・日本皮膚科学会京滋地方会

詳細情報

• CRID: 1390001205185619456
• NII論文ID: 130003844372
• DOI: 10.11340/skinresearch2002.1.7
• COI: 1:CAS:528:DC%2BD38Xjs1OltLw%3D
• ISSN: 18839614
• ISSN: 13471813
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可